Krystal Biotech stock falls 4.1 percent, 17.2 percent below high

Published on 10/17/2026 at 19:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The target rose to USD 416.00 from USD 386.00 on October 15, 2026. Krystal Biotech stock was USD 316.58 on October 16, 2026, down 4.1 percent on Nasdaq.

Analyst target and price range

Citi raised its target from USD 386.00 to USD 416.00 on October 15, 2026.
Krystal Biotech's 52-week range was USD 183.03 to USD 382.54 on October 16, 2026.
Krystal Biotech stock last traded at USD 316.58 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.07 percent versus the prior close.
Krystal Biotech is scheduled to report third-quarter results on November 2, 2026.

KRYS, US5011471027, Illustration mit AI erstellt.

Krystal Biotech (ISIN US5011471027) fell 4.07 percent on Nasdaq on October 16, 2026, leaving the stock 17.24 percent below its 52-week high of USD 382.54. The last Nasdaq price was USD 316.58 on October 16, 2026 at 4:00 p.m. ET.

Target gap remains material

On October 15, 2026, Citi lifted its price target for Krystal Biotech from USD 386.00 to USD 416.00 and retained a Buy rating, as Markets Insider reported. The new target lies 31.41 percent above the October 16 price, using the same USD basis.

Range and valuation set the frame

Krystal Biotech traded within a 52-week range of USD 183.03 to USD 382.54 as of October 16, 2026. Its latest price was 17.24 percent below the high and 72.97 percent above the low. Trading volume was 226,220 shares, versus an average volume of 363,390 shares, a 37.72 percent gap below the average.

The company had a market capitalization of USD 9.4 billion and a price-to-earnings ratio of 39.67 as of October 16, 2026. Krystal Biotech describes itself as a biotechnology company developing and commercializing genetic medicines for rare diseases.

Comparison with peers

KRYS (Nasdaq, USD): minus 4.07 percent, P/E 39.67, market capitalization USD 9.4 billion.

Vertex Pharmaceuticals (Nasdaq, USD): minus 1.77 percent, P/E 29.09, market capitalization USD 126.7 billion.

Alnylam Pharmaceuticals (Nasdaq, USD): minus 0.94 percent, P/E 39.16, market capitalization USD 31.0 billion.

Next reporting date is November 2

Krystal Biotech is estimated to report third-quarter 2026 results before the market opens on November 2, 2026, with the conference call scheduled for 8:30 a.m. ET, according to MarketBeat. That date gives the valuation and target debate a defined next checkpoint.

Price stays below the yearly high

Krystal Biotech ended the October 16 session 17.24 percent below its 52-week high, while its market capitalization stood at USD 9.4 billion and the next reporting date was November 2, 2026.